Although the use of hormone inhibitors, such as tamoxifen, fulvestrant, and aromatase inhibitors, has remained the mainstay of ER + breast cancer treatment, the emergence of resistance has led to the addition of CDK4/6 inhibitors to this therapy. Here, ESR1 is linked to breast carcinoma.